Filtered By:
Condition: Ischemic Stroke
Drug: Plavix
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 1287 results found since Jan 2013.
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)
CONCLUSION: The aim of the GENPAD study is to evaluate the efficacy, safety, and cost-effectiveness of a genotype-guided antithrombotic treatment strategy compared to conventional clopidogrel treatment in PAD patients.PMID:35988587 | DOI:10.1016/j.ahj.2022.08.001
Source: Atherosclerosis - August 21, 2022 Category: Cardiology Authors: J Kranendonk L H Willems Rj van der Vijver-Coppen M Coenen E Adang R Donders C J Zeebregts Vhm Deneer Mmpj Reijnen C Kramers M C Warl é Source Type: research
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials
ConclusionThe prognosis of patients with an ischemic stroke or transient ischemic attack is improved with antiplatelets. Cilostazol showed the best risk-benefit characteristics without trade-off with the risk of major bleeding. Improved stroke recurrence with intensified antiplatelet regimens is counterbalanced with higher bleeding risk, and consequently, mortality remains unaffected. Treatment decisions in stroke survivals should integrate the assessment of bleeding risk for better identification of patients with the highest benefit of treatment intensification. Systematic review registrationProspero registration number: ...
Source: PLoS One - August 17, 2022 Category: Biomedical Science Authors: D ániel Tornyos Source Type: research
Pharmacogenetics of Antiplatelet Therapy
Annu Rev Pharmacol Toxicol. 2022 Aug 1. doi: 10.1146/annurev-pharmtox-051921-092701. Online ahead of print.ABSTRACTAntiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active clopidogrel metabolites, have high on-treatment platelet reactivity and increased ischemic risk. Pro...
Source: Annual Review of Pharmacology and Toxicology - August 1, 2022 Category: Drugs & Pharmacology Authors: Matteo Castrichini Jasmine A Luzum Naveen Pereira Source Type: research
The role of < em > CYP2C19 < /em > genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack
Expert Rev Clin Pharmacol. 2022 Aug 1. doi: 10.1080/17512433.2022.2108401. Online ahead of print.ABSTRACTINTRODUCTION: Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA). Conversion of clopidogrel to its active metabolite by hepatic cytochrome P450-2C19 (CYP2C19) is essential for the inhibition of the P2Y12 receptor and subsequent platelet aggregation to prevent thrombotic events. CYP2C19 is highly polymorphic, with over 30 loss of function (LoF) alleles. This review considers whether there is sufficient data to support genotype guided antip...
Source: Expert Review of Clinical Pharmacology - August 1, 2022 Category: Drugs & Pharmacology Authors: John H McDermott Marc Leach Dwaipayan Sen Craig J Smith William G Newman Philip M Bath Source Type: research
Pharmacogenetics of Antiplatelet Therapy
Annu Rev Pharmacol Toxicol. 2022 Aug 1. doi: 10.1146/annurev-pharmtox-051921-092701. Online ahead of print.ABSTRACTAntiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active clopidogrel metabolites, have high on-treatment platelet reactivity and increased ischemic risk. Pro...
Source: Annual Review of Pharmacology and Toxicology - August 1, 2022 Category: Drugs & Pharmacology Authors: Matteo Castrichini Jasmine A Luzum Naveen Pereira Source Type: research
The role of < em > CYP2C19 < /em > genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack
Expert Rev Clin Pharmacol. 2022 Aug 1. doi: 10.1080/17512433.2022.2108401. Online ahead of print.ABSTRACTINTRODUCTION: Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA). Conversion of clopidogrel to its active metabolite by hepatic cytochrome P450-2C19 (CYP2C19) is essential for the inhibition of the P2Y12 receptor and subsequent platelet aggregation to prevent thrombotic events. CYP2C19 is highly polymorphic, with over 30 loss of function (LoF) alleles. This review considers whether there is sufficient data to support genotype guided antip...
Source: Expert Review of Clinical Pharmacology - August 1, 2022 Category: Drugs & Pharmacology Authors: John H McDermott Marc Leach Dwaipayan Sen Craig J Smith William G Newman Philip M Bath Source Type: research
